Isolated Christensenella Composition for Metabolic Disease Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The screening and application of novel Christensenella species for treating metabolic diseases like obesity, diabetes, hypertension, and fatty liver disease are hindered by their anaerobic nature, difficult cultivation, and the complexity of interactions in multi-microorganism mixtures, which disrupt intestinal homeostasis and make efficacy verification challenging.
Innovation Solution
Isolation of Christensenella sp. with high nucleotide identity and 16S rDNA similarity to specific strains, capable of producing short-chain fatty acids, particularly butyric acid, and formulated into compositions for therapeutic use, including oral and injectable forms, to treat metabolic diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mixtures of multiple microorganisms are used for treatment, then therapeutic effects may be enhanced, but the mechanism becomes more complex and interactions between microorganisms are poorly understood
Solution Approach 1:
The patent extracts and isolates a single effective microorganism (Christensenella sp.) from complex multi-microorganism mixtures. By separating the active component from the mixture, the invention simplifies the treatment mechanism while maintaining therapeutic efficacy, making it easier to understand and verify the specific作用的 of the isolated strain.
Solution Approach 2:
The invention segments the complex multi-microorganism system into individual strains for separate study and application. This segmentation allows for independent characterization of each strain's properties, mechanisms, and effects, thereby reducing overall system complexity while preserving beneficial therapeutic effects.
2Reliability
If mixtures of multiple microorganisms are used, then potential synergistic effects may be achieved, but the impact on intestinal microbiota homeostasis becomes difficult to control
Solution Approach 1:
The patent extracts a single well-characterized strain (Christensenella sp.) from complex mixtures, enabling precise control over the introduced microorganism population. This extraction approach minimizes unpredictable interactions with native microbiota while maintaining therapeutic benefits, thereby better preserving intestinal homeostasis.
3Reliability
If anaerobic Christensenella bacteria are used for treatment, then metabolic disease effects may be achieved, but in vitro verification is difficult due to anaerobic nature
Solution Approach 1:
The patent employs intermediaries such as butyric acid production as a measurable marker to verify the presence and activity of anaerobic Christensenella sp. in vitro. By measuring these intermediary products rather than directly observing anaerobic bacterial activity, the invention enables indirect but reliable verification of therapeutic strain function without requiring complex anaerobic experimental conditions.
4Reliability
If anaerobic Christensenella bacteria are used for treatment, then potential therapeutic benefits may be achieved, but in vivo animal experiments face challenges in maintaining stable viable bacteria numbers
Solution Approach 1:
The patent utilizes the natural butyric acid production capability of Christensenella sp. as a self-indicating mechanism. The bacteria's metabolic activity (butyric acid production) serves as an inherent marker that can be detected to confirm presence and viability, eliminating the need for complex external monitoring systems and enabling more stable experimental conditions.
5Adaptability or versatility
If novel Christensenella species are screened from microorganism resources, then new therapeutic candidates may be discovered, but screening presents great challenges due to difficulty of cultivation
Solution Approach 1:
The patent creates a standardized reference strain (Christensenella sp. with specific 16S rDNA sequence and butyric acid production capability) that serves as a template for identifying and characterizing novel species. This reference copy enables systematic screening by providing a benchmark for comparison, thereby simplifying the discovery process for new therapeutic candidates while maintaining cultivation feasibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Christensenella sp. compositions effectively reduce liver weight, improve glucose tolerance, enhance insulin sensitivity, and alleviate metabolic disorders by modulating gut microbiota, without affecting food intake, and can be used in medicaments, health care products, or food products.
Implementation Method 1
The Christensenella sp. is capable of high-yield production of butyric acid and acetic acid
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3
AI summary
The present invention provides an isolated Christensenella, a composition containing same, and a use thereof. The present invention can be used for treating, preventing, or alleviating obesity, obesity-induced metabolic disorders, diabetes, inflammation, liver and kidney diseases, liver diseases, cardiovascular and cerebrovascular diseases and the like.